Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

TCM (570 HK): Sinopharm's $4.60/Share Offer

Quiddity Advisors

Event-Driven

China Traditional Chinese Medicine / Event-Driven

China Traditional Chinese Medicine (570 HK)

<ul>
<li>A 14.8% gain month-to-date, including this past Monday's 6.5% pop - you just knew something positive was taking place behind closed doors. And leaking its way into the public.   </li>
<li>So it was no real surprise to read in the latest<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0815/2024081500841.pdf" target="_blank" rel="noopener"> monthly update announcement</a> on the HKEx that various regulatory approvals are almost, but not quite, satisfied.</li>
<li>The wording in the announcement strikes a positive tone. Even remaining conservative on the timeline, this <em>could</em> be wrapped up before year-end. </li>
</ul>


A 14.8% gain month-to-date, including this past Monday's 6.5% pop - you just knew something positive was taking place behind closed doors. And leaking its way into the public.   
So it was no real surprise to read in the latest monthly update announcement on the HKEx that various regulatory approvals are almost, but not quite, satisfied.
The wording in the announcement strikes a positive tone. Even remaining conservative on the timeline, this could be wrapped up before year-end. 


China Traditional Chinese Medicine

TCM (570 HK): A Spoonful Of Sugar ...